Two Asian regulators take recall action over plasticisers in Augmentin formulations
This article was originally published in Scrip
Drug regulatory authorities in Hong Kong and Taiwan have ordered recalls of flavoured paediatric formulations of GlaxoSmithKline's antibacterial Augmentin (amoxicillin clavulanate) after they were found to contain trace amounts of plasticising agents.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.